Fig. 6
Expression of PRMT5 and LSD1 are positively associated in breast cancer patients (A) LSD1 (left) and PRMT5 (right) mRNA expression levels in normal (n = 113) and breast cancer tissues (n = 1109) in the TCGA microarray database. (B) Kaplan–Meier survival analysis of the relationship between relapse-free survival (upper), overall survival (lower) and the expression LSD1 (left) or PRMT5 (right), Statistical significance was determined by log-rank test. (C) Representative immunohistochemical labeling of LSD1 and PRMT5 (brown) in different breast cancer specimens with high, middle and low expression of PRMT5 and LSD1 as indicated. The nuclei were counterstained with hematoxylin (blue). Scale bars = 50 μm. (D) The relationship between LSD1 and PRMT5 expression in breast cancers was assessed by χ2 analysis, and the strength of correlation was evaluated by Pearson correlation coefficient. Statistical significance was defined as p < 0.05. (E) Analysis of public clinical datasets for the expression of PRMT5 and LSD1 in an RNA-sequencing dataset (left) and a DNA microarray dataset (right). The relative mRNA level of LSD1 was plotted against that of PRMT5. Correlations were analyzed using Pearson correlation method. (F) A proposed model illustrates the dual mode of transcriptional regulation of Slug conferred by PRMT5 and LSD1, leading to an EMT and metastasis and pharmacologic co-inhibition of PRMT5 and LSD1 synergistically suppresses breast cancer progression (see Discussion)